CRISPR–Cas9 mediated repression of BACE1 for amyloid-beta reduction in early-stage Alzheimer’s disease: A meta-analysis
DOI:
https://doi.org/10.55629/pakjpathol.v36i3.942Abstract
Objective: To assess the efficacy of CRISPR–Cas9-mediated repression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in reducing amyloid-beta (Aβ) accumulation, neuropathological changes, and cognitive deficits in preclinical Alzheimer’s disease (AD) models.
Data Sources: A systematic search (2017–2024) was conducted in PubMed, Scopus, Web of Science, and Google Scholar, following PRISMA 2020 guidelines.
Study Selection: Ten preclinical studies using rodent or neuronal AD models with CRISPR–Cas9 or CRISPR interference targeting BACE1 were included.
Data Extraction: Extracted data included Aβ₄₀/₄₂ levels, BACE1 expression, plaque burden, neuronal integrity, neuroinflammation, and cognitive performance.
Data Synthesis: Meta-analysis (RevMan 5.4, STATA 17) showed significant reductions in Aβ₄₀/₄₂ (SMD = –1.45), BACE1 expression (SMD = –1.73), and plaque burden (SMD = –1.38). Qualitative findings indicated improved neuronal survival, reduced inflammation, and cognitive benefits.
Conclusions: CRISPR–Cas9 repression of BACE1 effectively attenuates amyloid pathology and supports cognitive improvements in preclinical AD models, underscoring its promise for translational CRISPR-based therapies.
Keywords: Alzheimer’s Disease, CRISPR, BACE1, Amyloid-beta, Meta-analysis, Gene editing.
References
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019; 14(1): 32. DOI: https://doi.org/10.1186/s13024-019-0333-5.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016; 8(6): 595–608. DOI: https://doi.org/10.15252/emmm.201606210
Wang Q, Xiao B, Cui S, Song H, Qian Y, Dong L, et al. Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD. Dis Model Mech. 2014; 7(12): 1385–95.
DOI: https://doi.org/10.1242/dmm.018218
Morroni F, Caccamo A. Advances and challenges in gene therapy for Alzheimer’s disease. J Alzheimers Dis. 2024; 101(S1): S417–S431. DOI: https://doi.org/10.3233/JAD-230783
Bahn G, Park J-S, Yun UJ, Lee YJ, Choi Y, Park JS, et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. Proc Natl Acad Sci USA. 2019; 116(25): 12516–23. DOI: https://doi.org/10.1073/pnas.1819541116
Barman NC, Khan NM, Islam M, Nain Z, Roy RK, Haque A, Barman SK. CRISPR-Cas9: A promising genome editing therapeutic tool for Alzheimer’s disease-A narrative review. Neurol Ther. 2020; 9(2):419–34. DOI: https://doi.org/10.1007/s40120-020-00218-z
Liu D, Zhang H, Liu C, Liu J, Liu Y, Bai N, et al. Systematic review and meta-analysis of the association between ABCA7 common variants and Alzheimer’s disease in non-Hispanic White and Asian cohorts. Front Aging Neurosci. 2024; 16: 1406573. DOI: https://doi.org/10.3389/fnagi.2024.1406573
Lu L, Yu X, Cai Y, Sun M, Yang H. Application of CRISPR/Cas9 in Alzheimer’s disease. Front Neurosci. 2021; 15: 803894. DOI: https://doi.org/10.3389/fnins.2021.803894.
Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, et al. CRISPR/Cas9 gene editing: New hope for Alzheimer’s disease therapeutics. J Adv Res. 2022; 40: 207–21. DOI: https://doi.org/10.1016/j.jare.2021.07.001.
Raffaele I, Cipriano GL, Anchesi I, Oddo S, Silvestro S. CRISPR/Cas9 and iPSC-based therapeutic approaches in Alzheimer’s disease. Antioxidants (Basel). 2025; 14(7): 781. DOI: https://doi.org/10.3390/antiox14070781.
Inoue K, Oliveira LM, Abeliovich A. CRISPR transcriptional activation analysis unmasks an occult γ-secretase processivity defect in familial Alzheimer’s disease skin fibroblasts. Cell Rep. 2017; 21(7): 1727–36. DOI: https://doi.org/10.1016/j.celrep.2017.10.075
Khan MS, Qureshi N, Khan R, Son Y-O, Maqbool T. CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer’s disease: progress and prospects. Front Cell Neurosci. 2025; 19: 1578138.
DOI: https://doi.org/10.3389/fncel.2025.1578138
Asanomi Y, Kimura T, Shimoda N, Shigemizu D, Niida S, Ozaki K. CRISPR/Cas9-mediated knock-in cells of the late-onset alzheimer’s disease-risk variant, SHARPIN G186R, reveal reduced NF-κB pathway and accelerated Aβ secretion. J Hum Genet. 2024; 69(5): 171–6. DOI: https://doi.org/10.1038/s10038-024-01224-x.
Jiang H, Tang M, Xu Z, Wang Y, Li M, Zheng S, et al. CRISPR/Cas9 system and its applications in nervous system diseases. Genes Dis. 2024; 11(2): 675–86. DOI: https://doi.org/10.1016/j.gendis.2023.03.017
Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023; 211: 115522.
DOI: https://doi.org/10.1016/j.bcp.2023.115522
Du Y, Zhao Y, Li C, Zheng Q, Tian J, Li Z, et al. Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes. J Exp Med. 2018; 215(6): 1665–77. DOI: https://doi.org/10.1084/jem.20172209.
Adji AS, Widjaja JS, Wardani VAK, Muhammad AH, Handajani F, Putra HBP, et al. A review of CRISPR Cas9 for Alzheimer’s disease: Treatment strategies and could target APOE e4, APP, and PSEN-1 gene using CRISPR cas9 prevent the patient from Alzheimer’s disease? Open Access Maced J Med Sci. 2022; 10(F): 745–57. DOI: https://doi.org/10.3889/oamjms.2022.9053
Rahimi A, Sameei P, Mousavi S, Ghaderi K, Hassani A, Hassani S, Alipour S. Application of CRISPR/Cas9 system in the treatment of Alzheimer’s disease and neurodegenerative diseases. Mol Neurobiol. 2024; 61(11): 9416–31. DOI: https://doi.org/10.1007/s12035-024-04143-2.
Tripathi S, Sharma Y, Rane R, Kumar D. CRISPR/Cas9 gene editing: A novel approach towards Alzheimer’s disease treatment. CNS Neurol Disord Drug Targets. 2024; 23(12): 1405-24. DOI: https://doi.org/10.2174/01187152732837 86240408034408
Sun J, Roy S. CRISPR Therapies for Alzheimer’s Disease. In: Tuszynski, M.H. (eds) Translational Neuroscience. Springer, Cham. DOI: https://doi.org/10.1007/978-3-031-89307-0_12
Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther. 2014; 6(9) :89.
DOI: https://doi.org/10.1186/s13195-014-0089-7.
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346(6213): 1258096. DOI: https://doi.org/10.1126/science.1258096
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2018; 378(18) :1691–703. DOI: https://doi.org/10.1056/NEJMoa1706441
Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020; 5(1): 1.
DOI: https://doi.org/10.1038/s41392-019-0089-y
Chen F, Fang S, Du Y, Ghosh A, Reed MN, Long Y, et al. CRISPR/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP/PS1 mice. Aging (Albany NY). 2021; 13(5): 6634–56.
DOI: https://doi.org/10.18632/aging.202501.
Shareena G, Viswalingam V, Rajput MS, Kumar D. CRISPR/Cas9 gene editing: A new hope for Alzheimer’s disease. In: Targeted Therapy for the Central Nervous System. Amsterdam: Elsevier; 2025. p. 301–23.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Atta Ur Rehman Khan, Safdar Manzoor, Muhammad Sarmad, Muhammad Rizwan Anwar

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
